Demographic and baseline characteristics of DLBCL patients (all patients [ITT population] and BEP population) in the 3 discovery cohorts and the GOYA study
| . | Arthur . | Schmitz . | Reddy . | GOYA . | ||||
|---|---|---|---|---|---|---|---|---|
| Characteristic* . | All (N = 404) . | BEP RNA-seq (n = 372) . | All (N = 554) . | BEP RNA-seq (n = 234) . | All (N = 1001) . | BEP RNA-seq (n = 455) . | All (N = 1414) . | BEP RNA-seq (n = 552) . |
| Median follow-up, y | 11.7 | 11.5 | 10.5 | 10.5 | 10.4 | 8.9 | 4.0 | 4.1 |
| Age, n | 404 | 372 | 546 | 234 | 950 | 448 | 1414 | 552 |
| Median (range), y | 64 (16-92) | 64 (16-92) | 62 (14-92) | 61 (16-92) | 62 (3.1-93.4) | 63 (3.1-93.4) | 62 (18-86) | 63 (18-85) |
| Female | 153 (37.9) | 143 (38.4) | 241 (43.5) | 95 (40.6) | 434 (43.5)† | 196 (43.1) | 664 (47.0) | 264 (47.8) |
| IPI, n | 385 | 354 | 339 | 189 | 761 | 388 | 1414 | 552 |
| Low | 128 (33.3) | 118 (33.3) | 103 (30.4) | 77 (40.7) | 244 (32.1) | 120 (30.9) | 282 (19.9) | 107 (19.4) |
| Low-intermediate | 105 (27.3) | 97 (27.4) | 87 (25.7) | 45 (23.8) | 180 (23.7) | 94 (24.2) | 500 (35.4) | 194 (35.1) |
| High-intermediate | 71 (18.4) | 64 (18.1) | 84 (24.8) | 44 (23.3) | 192 (25.2) | 101 (26.0) | 412 (29.1) | 161 (29.2) |
| High | 81 (21.0) | 75 (21.2) | 65 (19.2) | 23 (12.2) | 145 (19.1) | 73 (18.8) | 220 (15.6) | 90 (16.3) |
| Ann Arbor stage at diagnosis, n | 404 | 372 | 458 | 231 | 974 | 448 | 1413 | 552 |
| I/II | 180 (44.6) | 165 (44.3) | 200 (43.7) | 109 (47.2) | 384 (39.4) | 176 (39.3) | 340 (24.1) | 134 (24.3) |
| III/IV | 224 (55.4) | 207 (55.7) | 258 (56.3) | 122 (52.8) | 590 (60.6) | 272 (60.7) | 1073 (75.9) | 418 (75.7) |
| COO, n | 388 | 364 | 554 | 234 | 775 | 455 | 933 | 538 |
| GCB | 217 (55.9) | 204 (56.0) | 164 (29.6) | 110 (47.0) | 331 (42.7) | 197 (43.3) | 540 (57.9) | 298 (55.4) |
| ABC | 129 (33.3) | 120 (33.0) | 279 (50.4) | 82 (35.0) | 313 (40.4) | 187 (41.1) | 243 (26.1) | 151 (28.1) |
| Unclassified | 42 (10.8) | 40 (11.0) | 111 (20.0) | 42 (18.0) | 131 (16.9) | 71 (15.6) | 150 (16.1) | 89 (16.5) |
| DHITsig, n | 204 | 204 | 134 | 107 | 207 | 197 | 298 | 298 |
| Positive | 60 (29.4) | 60 (29.4) | 24 (17.9) | 21 (19.6) | 57 (27.5) | 53 (26.9) | 32 (10.7) | 32 (10.7) |
| Negative | 144 (70.6) | 144 (70.6) | 110 (82.1) | 86 (80.4) | 150 (72.5) | 144 (73.1) | 266 (89.3) | 266 (89.26) |
| BCL2 by IHC, n | 364 | 343 | 0 | 0 | 462 | 230 | 755 | 433 |
| Positive | 245 (67.3) | 235 (68.5) | – | – | 323 (69.9) | 172 (74.8) | 363 (48.1) | 206 (47.6) |
| Negative | 119 (32.7) | 108 (31.5) | – | – | 139 (30.1) | 58 (25.2) | 392 (51.9) | 227 (52.4) |
| Number of chemotherapy cycles, n | – | – | – | – | – | – | 1414 | 552 |
| 6 | – | – | – | – | – | – | 1045 (73.9) | 402 (72.8) |
| 8 | – | – | – | – | – | – | 369 (26.1) | 150 (27.2) |
| Geographic region, n | 1414 | 552 | ||||||
| Asia | – | – | – | – | – | – | 514 (36.4) | 89 (16.1) |
| Eastern Europe | – | – | – | – | – | – | 196 (13.9) | 122 (22.1) |
| Western Europe | – | – | – | – | – | – | 426 (30.1) | 216 (39.1) |
| North America | – | – | – | – | – | – | 216 (15.3) | 93 (16.9) |
| Other | – | – | – | – | – | – | 62 (4.4) | 32 (5.8) |
| . | Arthur . | Schmitz . | Reddy . | GOYA . | ||||
|---|---|---|---|---|---|---|---|---|
| Characteristic* . | All (N = 404) . | BEP RNA-seq (n = 372) . | All (N = 554) . | BEP RNA-seq (n = 234) . | All (N = 1001) . | BEP RNA-seq (n = 455) . | All (N = 1414) . | BEP RNA-seq (n = 552) . |
| Median follow-up, y | 11.7 | 11.5 | 10.5 | 10.5 | 10.4 | 8.9 | 4.0 | 4.1 |
| Age, n | 404 | 372 | 546 | 234 | 950 | 448 | 1414 | 552 |
| Median (range), y | 64 (16-92) | 64 (16-92) | 62 (14-92) | 61 (16-92) | 62 (3.1-93.4) | 63 (3.1-93.4) | 62 (18-86) | 63 (18-85) |
| Female | 153 (37.9) | 143 (38.4) | 241 (43.5) | 95 (40.6) | 434 (43.5)† | 196 (43.1) | 664 (47.0) | 264 (47.8) |
| IPI, n | 385 | 354 | 339 | 189 | 761 | 388 | 1414 | 552 |
| Low | 128 (33.3) | 118 (33.3) | 103 (30.4) | 77 (40.7) | 244 (32.1) | 120 (30.9) | 282 (19.9) | 107 (19.4) |
| Low-intermediate | 105 (27.3) | 97 (27.4) | 87 (25.7) | 45 (23.8) | 180 (23.7) | 94 (24.2) | 500 (35.4) | 194 (35.1) |
| High-intermediate | 71 (18.4) | 64 (18.1) | 84 (24.8) | 44 (23.3) | 192 (25.2) | 101 (26.0) | 412 (29.1) | 161 (29.2) |
| High | 81 (21.0) | 75 (21.2) | 65 (19.2) | 23 (12.2) | 145 (19.1) | 73 (18.8) | 220 (15.6) | 90 (16.3) |
| Ann Arbor stage at diagnosis, n | 404 | 372 | 458 | 231 | 974 | 448 | 1413 | 552 |
| I/II | 180 (44.6) | 165 (44.3) | 200 (43.7) | 109 (47.2) | 384 (39.4) | 176 (39.3) | 340 (24.1) | 134 (24.3) |
| III/IV | 224 (55.4) | 207 (55.7) | 258 (56.3) | 122 (52.8) | 590 (60.6) | 272 (60.7) | 1073 (75.9) | 418 (75.7) |
| COO, n | 388 | 364 | 554 | 234 | 775 | 455 | 933 | 538 |
| GCB | 217 (55.9) | 204 (56.0) | 164 (29.6) | 110 (47.0) | 331 (42.7) | 197 (43.3) | 540 (57.9) | 298 (55.4) |
| ABC | 129 (33.3) | 120 (33.0) | 279 (50.4) | 82 (35.0) | 313 (40.4) | 187 (41.1) | 243 (26.1) | 151 (28.1) |
| Unclassified | 42 (10.8) | 40 (11.0) | 111 (20.0) | 42 (18.0) | 131 (16.9) | 71 (15.6) | 150 (16.1) | 89 (16.5) |
| DHITsig, n | 204 | 204 | 134 | 107 | 207 | 197 | 298 | 298 |
| Positive | 60 (29.4) | 60 (29.4) | 24 (17.9) | 21 (19.6) | 57 (27.5) | 53 (26.9) | 32 (10.7) | 32 (10.7) |
| Negative | 144 (70.6) | 144 (70.6) | 110 (82.1) | 86 (80.4) | 150 (72.5) | 144 (73.1) | 266 (89.3) | 266 (89.26) |
| BCL2 by IHC, n | 364 | 343 | 0 | 0 | 462 | 230 | 755 | 433 |
| Positive | 245 (67.3) | 235 (68.5) | – | – | 323 (69.9) | 172 (74.8) | 363 (48.1) | 206 (47.6) |
| Negative | 119 (32.7) | 108 (31.5) | – | – | 139 (30.1) | 58 (25.2) | 392 (51.9) | 227 (52.4) |
| Number of chemotherapy cycles, n | – | – | – | – | – | – | 1414 | 552 |
| 6 | – | – | – | – | – | – | 1045 (73.9) | 402 (72.8) |
| 8 | – | – | – | – | – | – | 369 (26.1) | 150 (27.2) |
| Geographic region, n | 1414 | 552 | ||||||
| Asia | – | – | – | – | – | – | 514 (36.4) | 89 (16.1) |
| Eastern Europe | – | – | – | – | – | – | 196 (13.9) | 122 (22.1) |
| Western Europe | – | – | – | – | – | – | 426 (30.1) | 216 (39.1) |
| North America | – | – | – | – | – | – | 216 (15.3) | 93 (16.9) |
| Other | – | – | – | – | – | – | 62 (4.4) | 32 (5.8) |